|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/05 | |
| A61K 38/07 | |||
| A61K 31/145 | |||
| A61P 35/02 | |||
| C12Q 1/68 | |||
| G01N 33/574 |
| (11) | Patento numeris | 3030251 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14752766.7 |
| Europos patento paraiškos padavimo data | 2014-08-08 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-06-15 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-10-24 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/050333 |
| Data | 2014-08-08 |
| (87) | Numeris | WO 2015/021376 |
| Data | 2015-02-12 |
| (30) | Numeris | Data | Šalis |
| 201361863809 P | 2013-08-08 | US | |
| 201361875954 P | 2013-09-10 | US | |
| 201462005904 P | 2014-05-30 | US |
| (72) |
TUCH, Brian, US
DEGENHARDT, Jeremiah, US
LOEHR, Andrea, US
KWEI, Kevin, US
KIRK, Christopher, J., US
|
| (73) |
Onyx Therapeutics, Inc.,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
|
| (54) | IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE |
| IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE |